Natreon’s Sensoril ashwagandha improves strength training adaptations and recovery in recently published clinical trial
Natreon, a leader in Ayurvedic ingredient research and innovation, announced its latest results in the recently published S.T.A.R. (Strength Training Adaptations and Recovery) trial with its clinically studied Sensoril ashwagandha.
Sensoril is a patented ashwagandha extract supported by more than 10 clinical studies designed to enhance adaptogenic health benefits.
Sensoril is derived from a unique blend of both leaves and roots of the Withania somnifera plant to provide optimal efficacy and bioactive diversity. During this trial, Sensoril showed significant improvement in both upper and lower-body strength in recreationally active men over a 12-week resistance training and supplementation period.
This US-based study, conducted at The Center for Applied Health Sciences, was a 12-week, randomised, parallel-group, placebo-controlled, clinical trial to examine the impact of Sensoril on strength training adaptations. Subjects were all healthy males between the ages of 18–45 years who were recreationally active, training no more than 2–3 days/week.
Subjects were randomised to either receive Sensoril 500 mg/day, or a placebo. Subjects in the Sensoril group significantly improved their squat strength by 90%, an increase in leg strength of more than 9 kg, compared with the placebo.
There was also a 60% improvement upper body strength (as assessed by the bench press) by more than 4 kg. Sensoril was also found to significantly improve Perceived Recovery by 14% compared with the baseline while the placebo group showed a significant increase in muscle soreness by more than 40%.
“The results of our study help establish an evidence base for this impressive Ayurvedic herb in sports nutrition. The Center for Applied Health Sciences is eager to continue its strategic partnership with Natreon to continue bringing high quality research to consumers,” stated Dr Tim Ziegenfuss, CEO of The Center for Applied Health Sciences.
The significant increases in upper and lower body strength with Sensoril continues to add to the successful clinical substantiation supporting Sensoril’s ability to enhance performance, improve energy, reduce symptoms of everyday stress and enhance focus.
“Sensoril is a wonderful product and we are proud to work with US based institutes such as CAHS to advance the sports nutrition utility of Sensoril. Furthermore, we are happy that the University of Pittsburgh Medical Center has two investigator initiated studies with Sensoril and a third study in progress at UCLA and University of Maryland. We will continue to demonstrate our focus on expanding science with reputable US institutes,” said Dr Sanni Raju, CEO of Natreon.